Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Celgene International Sarl has announced that Thalidomide Pharmion has received full marketing authorization from the European Commission for use in combination with melphalan and prednisone as a treatment for patients with newly diagnosed multiple myeloma.
Subscribe to our email newsletter
Aart Brouwer, president of Celgene International, said: “We are working diligently with local regulatory authorities to determine next steps for pricing, reimbursement and distribution plans for all EU member states so that Thalidomide Pharmion will be available for eligible patients as quickly as possible.”